We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

ERCC1 Targeted Trial (ET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00801736
Recruitment Status : Terminated (The antibody used did not appear prognostic/predictive based on interim results.)
First Posted : December 3, 2008
Last Update Posted : December 10, 2013
Eli Lilly and Company
Cancer Research UK
Information provided by (Responsible Party):
University College, London

Brief Summary:
Lung cancer is the leading cause of cancer death in the UK, leading to 34 000 deaths each year (22% of cancer deaths). Non-small cell lung cancer (NSCLC) is the most common histology, accounting for approximately 80% of cases and most present with advanced, stage IIIb or IV disease. The recommended treatment for advanced disease is a doublet platinum-based chemotherapy, although the survival benefits are modest. Even among those fit enough for chemotherapy, the response rate is only 20-40%, and median survival averages 9-10 months with the newer platinum-containing chemotherapy regimen (Schiller et al, 2002; Rudd et al, 2005; Lee et al, 2007). Only 11% of patients went on to survive 2 years when treated with the newer gemcitabine/carboplatin regimen established by the London Lung Cancer Group (Rudd et al, 2005; Lee et al, 2007). New strategies are needed to further improve the prognosis of this disease.

Condition or disease Intervention/treatment Phase
Lung Cancer Drug: Cisplatin, Paclitaxel Phase 3

Detailed Description:


Primary objective

The trial will have two main objectives:

  • To detect an improvement in survival for ERCC1+ve patients treated with a non-platinum chemotherapy compared to platinum-based treatment.
  • To establish non-inferiority or improvement in survival for ERCC1-ve patients treated with a platinum-based chemotherapy compared to non-platinum treatment.

Secondary objectives

  • To examine progression-free survival, response rate and quality of life between the two treatment regimens, according to ERCC1 status.
  • To investigate whether the treatment effect differs according to histology (squamous vs. nonsquamous);gender (males vs. females); performance status
  • To undertake a cost-effectiveness analysis based on all patients, and according to ERCC1 status.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 648 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentre, Randomised, Phase III Trial of Platinum-based Chemotherapy Versus Non-platinum Chemotherapy, After ERCC1 Stratification, in Patients With Advanced/Metastatic Non-small Cell Lung Cancer
Study Start Date : October 2009
Actual Primary Completion Date : July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Platinum Arm
Cisplatin (IMP) / Pemetrexed (IMP)
Drug: Cisplatin, Paclitaxel
  • Cisplatin 75mg/m2, Day 1
  • Paclitaxel 175mg/m2, Day 1

Experimental: Non Platinum Arm
Paclitaxel (IMP) / Pemetrexed (IMP)
Drug: Cisplatin, Paclitaxel
  • Cisplatin 75mg/m2, Day 1
  • Paclitaxel 175mg/m2, Day 1

Primary Outcome Measures :
  1. Overall Survival [ Time Frame: Dec 2014 ]

Secondary Outcome Measures :
  1. Time to progression [ Time Frame: Dec 2014 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes


  1. Histological confirmation of non-squamous NSCLC
  2. Have a tissue biopsy available for sending to the central laboratory to determine ERCC1 status
  3. Presentation with stage IIIb (not amenable to curative treatment) or IV disease - staging scans must be no more than 28 days prior to registration. Patients with relapsed NSCLC must not have received prior chemotherapy or biological therapy (previous surgery or radical radiotherapy allowed)
  4. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours
  5. Either sex, at least 18 years of age
  6. ECOG performance status 0-1
  7. Estimated life expectancy of at least 8 weeks
  8. Adequate bone marrow function as evidenced by the following (assessed within 14 days of registration):

    • Absolute neutrophil count (ANC) ≥1.5 × 109/L
    • Platelet count ≥100 × 109/L
    • Haemoglobin ≥9 g/dL
  9. Adequate liver function as evidenced by the following (assessed within 14 days of registration):

    • Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
    • Aspartate transaminase (AST) ≤3 × ULN or ≤5 × ULN is acceptable with liver metastases
    • Alanine transaminase (ALT) ≤3 × ULN
  10. Adequate renal function as evidenced by the following (assessed within 14 days of registration):

    - GFR > 60ml/min as measured by creatinine clearance through EDTA. Alternatively, the Cockcroft and Gault formula may be used to estimate GFR, but if < 60 ml/min then EDTA should be performed.

  11. Previous palliative radiotherapy to non-target metastatic lesions is allowed for pain relief prior to starting chemotherapy
  12. Patients with stable brain metastases will be allowed to enrol. Stable brain metastases being defined as no progression of brain metastases 28 days after treatment as documented by a CT scan/MRI of the brain. Patients with incidentally discovered asymptomatic brain metastases may be enrolled and treated with trial chemotherapy without prior brain irradiation if deemed feasible by the treating physician
  13. Signed informed consent form
  14. Use of effective contraception during, and for 6 months after trial treatment by patients of reproductive potential and partners of reproductive potential. Patients who receive aprepitant (anti-emetic) must be willing to use an alternative or back-up method to hormonal contraceptives as aprepitant may reduce their efficacy. Female patients with childbearing potential must have a negative serum pregnancy test prior to registration.


  1. Cytologically or clinically diagnosed NSCLC
  2. Evidence of significant medical condition or laboratory finding which, in the opinion of the treating physician or chief investigator, makes it undesirable for the patient to participate in the trial
  3. Presence of uncontrolled brain or leptomeningeal metastases thought to require immediate radiotherapy
  4. Presence of clinically significant third-space fluid collections (for example, ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to trial entry
  5. Yellow fever vaccination received within the 30 days previous to study entry
  6. Unable to interrupt aspirin or other NSAIDs (for pemetrexed arms of the trial)
  7. Unable or unwilling to take vitamin B12 and folic acid (for pemetrexed arms of the trial)
  8. A history of prior malignant tumour, unless the patient has been without evidence of disease for at least 3 years or the tumour was a non-melanoma skin tumour or early cervical cancer
  9. Pregnant or lactating women
  10. Inability to comply with protocol or trial procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00801736

Layout table for location information
United Kingdom
University College London Hospitals
London, United Kingdom
Sponsors and Collaborators
University College, London
Eli Lilly and Company
Cancer Research UK
Layout table for investigator information
Principal Investigator: Siow M. Lee, MD, PhD, FRCP Cancer Research UK
Layout table for additonal information
Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT00801736    
Other Study ID Numbers: ISRCTN02370070
First Posted: December 3, 2008    Key Record Dates
Last Update Posted: December 10, 2013
Last Verified: December 2012
Keywords provided by University College, London:
Recurrent non-small cell lung cancer
Stage IIIB non-small cell lung cancer
Stage IV non-small cell lung cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action